Skip to main content
Top
Published in: International Journal of Hematology 1/2010

01-01-2010 | Case Report

Influenza A/pandemic 2009/H1N1 in the setting of allogeneic hematopoietic cell transplantation: a potentially catastrophic problem in a vulnerable population

Authors: Mohamed A. Kharfan-Dabaja, Ana Velez, Karla Richards, John N. Greene, Teresa Field, Ramon Sandin

Published in: International Journal of Hematology | Issue 1/2010

Login to get access

Abstract

We describe Influenza A/pandemic 2009/H1N1 in two allogeneic hematopoietic cell transplantation recipients. The main presentation in both cases consisted of flu-like symptoms manifesting as, fever, arthralgias and myalgias. The virus was isolated in one case from a throat swab and in another case following a bronchoalveolar lavage. Both patients received oseltamivir at a dose of 75 mg orally twice day. The dose of oseltamivir was increased to 150 mg twice per day due to the lack of improvement or progression of symptoms. In one case, clinical symptoms resolved without sequelae. In the second case, pulmonary symptomatology continued to deteriorate, despite aggressive polymicrobial treatment, requiring mechanical ventilation and ultimately the patient died from respiratory failure. These cases highlight the potentially serious effect of the ongoing Influenza A/pandemic 2009/H1N1 pandemic in this very vulnerable population and the urgent need to establish emergency preparedness strategies by oncology and bone marrow transplantation staff to face this serious healthcare challenge.
Literature
1.
go back to reference Update: novel Influenza A (H1N1) virus infection—Mexico, March–May 2009. MMWR Morb Mortal Wkly Rep 2009;58:467–470. Update: novel Influenza A (H1N1) virus infection—Mexico, March–May 2009. MMWR Morb Mortal Wkly Rep 2009;58:467–470.
4.
go back to reference Vaillant L, La Ruche G, Tarantola A, Barboza P. Epidemic intelligence team at InVS. Epidemiology of fatal cases associated with pandemic H1N1 influenza 2009. Euro Surveill. 2009;14:19309. Vaillant L, La Ruche G, Tarantola A, Barboza P. Epidemic intelligence team at InVS. Epidemiology of fatal cases associated with pandemic H1N1 influenza 2009. Euro Surveill. 2009;14:19309.
5.
go back to reference Oseltamivir-resistant novel Influenza A (H1N1) virus infection in two immunosuppressed patients—Seattle, WA, 2009. MMWR Morb Mortal Wkly Rep. 2009;58 (Dispatch, August 14);1–4. Oseltamivir-resistant novel Influenza A (H1N1) virus infection in two immunosuppressed patients—Seattle, WA, 2009. MMWR Morb Mortal Wkly Rep. 2009;58 (Dispatch, August 14);1–4.
6.
go back to reference Shinde V, Bridges CB, Uyeki TM, et al. Triple-reassortant swine influenza A (H1) in humans in the United States, 2005–2009. N Engl J Med. 2009;360:2616–25.CrossRefPubMed Shinde V, Bridges CB, Uyeki TM, et al. Triple-reassortant swine influenza A (H1) in humans in the United States, 2005–2009. N Engl J Med. 2009;360:2616–25.CrossRefPubMed
8.
go back to reference Cohen J. Swine flu outbreak. Out of Mexico? Scientists ponder swine flu’s origins. Science. 2009;324:700.CrossRefPubMed Cohen J. Swine flu outbreak. Out of Mexico? Scientists ponder swine flu’s origins. Science. 2009;324:700.CrossRefPubMed
9.
go back to reference Machado CM, Boas LS, Mendes AV, et al. Low mortality rates related to respiratory virus infections after bone marrow transplantation. Bone Marrow Transplant. 2003;31:695–700.CrossRefPubMed Machado CM, Boas LS, Mendes AV, et al. Low mortality rates related to respiratory virus infections after bone marrow transplantation. Bone Marrow Transplant. 2003;31:695–700.CrossRefPubMed
10.
go back to reference Chemaly RF, Torres HA, Aguilera EA, et al. Neuraminidase inhibitors improve outcome of patients with leukemia and influenza: an observational study. Clin Infect Dis. 2007;44:964–7.CrossRefPubMed Chemaly RF, Torres HA, Aguilera EA, et al. Neuraminidase inhibitors improve outcome of patients with leukemia and influenza: an observational study. Clin Infect Dis. 2007;44:964–7.CrossRefPubMed
11.
go back to reference Engelhard D, Nagler A, Hardan I, et al. Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients. Bone Marrow Transplant. 1993;11:1–5.PubMed Engelhard D, Nagler A, Hardan I, et al. Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients. Bone Marrow Transplant. 1993;11:1–5.PubMed
12.
go back to reference Cordonnier C, Labopin M, Chesnel V, et al. Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation. Clin Infect Dis. 2009;48:1392–401.CrossRefPubMed Cordonnier C, Labopin M, Chesnel V, et al. Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation. Clin Infect Dis. 2009;48:1392–401.CrossRefPubMed
13.
go back to reference Machado CM, Cardoso MRA, da Rocha IF, Boas LSV, Dulley FL, Pannuti CS. The benefit of influenza vaccination after bone marrow transplantation. Bone Marrow Transplant. 2005;36:897–900.CrossRefPubMed Machado CM, Cardoso MRA, da Rocha IF, Boas LSV, Dulley FL, Pannuti CS. The benefit of influenza vaccination after bone marrow transplantation. Bone Marrow Transplant. 2005;36:897–900.CrossRefPubMed
14.
go back to reference Weinstock DM, Gubareva LV, Zuccotti G. Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. N Engl J Med. 2003;348:867–8.CrossRefPubMed Weinstock DM, Gubareva LV, Zuccotti G. Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. N Engl J Med. 2003;348:867–8.CrossRefPubMed
15.
go back to reference Medeiros R, Rameix-Welti MA, Lorin V, et al. Failure of zanamivir therapy for pneumonia in a bone-marrow transplant recipient infected by a zanamivir-sensitive influenza A (H1N1) virus. Antivir Ther. 2007;12:571–6.PubMed Medeiros R, Rameix-Welti MA, Lorin V, et al. Failure of zanamivir therapy for pneumonia in a bone-marrow transplant recipient infected by a zanamivir-sensitive influenza A (H1N1) virus. Antivir Ther. 2007;12:571–6.PubMed
16.
go back to reference Khanna N, Steffen I, Studt JD, et al. Outcome of influenza infections in outpatients after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2009;11(2):100–5.CrossRefPubMed Khanna N, Steffen I, Studt JD, et al. Outcome of influenza infections in outpatients after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2009;11(2):100–5.CrossRefPubMed
17.
go back to reference Kobayashi S, Kimura F, Kobayashi A, Sato K, Motoyoshi K. Influenza virus reactivation after remission with oseltamivir treatment in a patient undergoing nonmyeloablative bone marrow transplantation. J Infect Chemother. 2008;14(4):308–10.CrossRefPubMed Kobayashi S, Kimura F, Kobayashi A, Sato K, Motoyoshi K. Influenza virus reactivation after remission with oseltamivir treatment in a patient undergoing nonmyeloablative bone marrow transplantation. J Infect Chemother. 2008;14(4):308–10.CrossRefPubMed
18.
go back to reference Wingard JR. Influenza: preparedness for an inevitable “Emergency” for oncology and BMT units. Natl Compr Canc Netw. 2008;6:215–22. Wingard JR. Influenza: preparedness for an inevitable “Emergency” for oncology and BMT units. Natl Compr Canc Netw. 2008;6:215–22.
Metadata
Title
Influenza A/pandemic 2009/H1N1 in the setting of allogeneic hematopoietic cell transplantation: a potentially catastrophic problem in a vulnerable population
Authors
Mohamed A. Kharfan-Dabaja
Ana Velez
Karla Richards
John N. Greene
Teresa Field
Ramon Sandin
Publication date
01-01-2010
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 1/2010
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-009-0464-5

Other articles of this Issue 1/2010

International Journal of Hematology 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine